Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group

Michael A. Arnold, James R. Anderson, Julie M. Gastier-Foster, Frederic G. Barr, Stephen X. Skapek, Douglas S. Hawkins, R. Beverly Raney, David M. Parham, Lisa A. Teot, Erin R. Rudzinski, David O. Walterhouse

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

BACKGROUND: Distinguishing alveolar rhabdomyosarcoma (ARMS) from embryonal rhabdomyosarcoma (ERMS) is of prognostic and therapeutic importance. Criteria for classifying these entities evolved significantly from 1995 to 2013. ARMS is associated with inferior outcome; therefore, patients with alveolar histology have generally been excluded from low-risk therapy. However, patients with ARMS and low-risk stage and group (Stage 1, Group I/II/orbit III; or Stage 2/3, Group I/II) were eligible for the Children's Oncology Group (COG) low-risk rhabdomyosarcoma (RMS) study D9602 from 1997 to 1999. The characteristics and outcomes of these patients have not been previously reported, and the histology of these cases has not been reviewed using current criteria.

PROCEDURE: We re-reviewed cases that were classified as ARMS on D9602 using current histologic criteria, determined PAX3/PAX7-FOXO1 fusion status, and compared these data with outcome for this unique group of patients.

RESULTS: Thirty-eight patients with ARMS were enrolled onto D9602. Only one-third of cases with slides available for re-review (11/33) remained classified as ARMS by current histologic criteria. Most cases were reclassified as ERMS (17/33, 51.5%). Cases that remained classified as ARMS were typically fusion-positive (8/11, 73%), therefore current classification results in a similar rate of fusion-positive ARMS for all clinical risk groups. In conjunction with data from COG intermediate-risk treatment protocol D9803, our data demonstrate excellent outcomes for fusion-negative ARMS with otherwise low-risk clinical features.

CONCLUSIONS: Patients with fusion-positive RMS with low-risk clinical features should be classified and treated as intermediate risk, while patients with fusion-negative ARMS could be appropriately treated with reduced intensity therapy.

Original languageEnglish (US)
Pages (from-to)634-639
Number of pages6
JournalPediatric blood & cancer
Volume63
Issue number4
DOIs
StatePublished - Apr 1 2016

Fingerprint

Alveolar Rhabdomyosarcoma
Histology
Embryonal Rhabdomyosarcoma
Rhabdomyosarcoma
Orbit
Clinical Protocols
Therapeutics

Keywords

  • alveolar rhabdomyosarcoma
  • D9602
  • D9803
  • embryonal rhabdomyosarcoma
  • fusion status
  • histology
  • low risk
  • outcomes
  • rhabdomyosarcoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features : A Report From the Children's Oncology Group. / Arnold, Michael A.; Anderson, James R.; Gastier-Foster, Julie M.; Barr, Frederic G.; Skapek, Stephen X.; Hawkins, Douglas S.; Raney, R. Beverly; Parham, David M.; Teot, Lisa A.; Rudzinski, Erin R.; Walterhouse, David O.

In: Pediatric blood & cancer, Vol. 63, No. 4, 01.04.2016, p. 634-639.

Research output: Contribution to journalArticle

Arnold, MA, Anderson, JR, Gastier-Foster, JM, Barr, FG, Skapek, SX, Hawkins, DS, Raney, RB, Parham, DM, Teot, LA, Rudzinski, ER & Walterhouse, DO 2016, 'Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group', Pediatric blood & cancer, vol. 63, no. 4, pp. 634-639. https://doi.org/10.1002/pbc.25862
Arnold, Michael A. ; Anderson, James R. ; Gastier-Foster, Julie M. ; Barr, Frederic G. ; Skapek, Stephen X. ; Hawkins, Douglas S. ; Raney, R. Beverly ; Parham, David M. ; Teot, Lisa A. ; Rudzinski, Erin R. ; Walterhouse, David O. / Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features : A Report From the Children's Oncology Group. In: Pediatric blood & cancer. 2016 ; Vol. 63, No. 4. pp. 634-639.
@article{d30c6c34863746bda2f20945d330c491,
title = "Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group",
abstract = "BACKGROUND: Distinguishing alveolar rhabdomyosarcoma (ARMS) from embryonal rhabdomyosarcoma (ERMS) is of prognostic and therapeutic importance. Criteria for classifying these entities evolved significantly from 1995 to 2013. ARMS is associated with inferior outcome; therefore, patients with alveolar histology have generally been excluded from low-risk therapy. However, patients with ARMS and low-risk stage and group (Stage 1, Group I/II/orbit III; or Stage 2/3, Group I/II) were eligible for the Children's Oncology Group (COG) low-risk rhabdomyosarcoma (RMS) study D9602 from 1997 to 1999. The characteristics and outcomes of these patients have not been previously reported, and the histology of these cases has not been reviewed using current criteria.PROCEDURE: We re-reviewed cases that were classified as ARMS on D9602 using current histologic criteria, determined PAX3/PAX7-FOXO1 fusion status, and compared these data with outcome for this unique group of patients.RESULTS: Thirty-eight patients with ARMS were enrolled onto D9602. Only one-third of cases with slides available for re-review (11/33) remained classified as ARMS by current histologic criteria. Most cases were reclassified as ERMS (17/33, 51.5{\%}). Cases that remained classified as ARMS were typically fusion-positive (8/11, 73{\%}), therefore current classification results in a similar rate of fusion-positive ARMS for all clinical risk groups. In conjunction with data from COG intermediate-risk treatment protocol D9803, our data demonstrate excellent outcomes for fusion-negative ARMS with otherwise low-risk clinical features.CONCLUSIONS: Patients with fusion-positive RMS with low-risk clinical features should be classified and treated as intermediate risk, while patients with fusion-negative ARMS could be appropriately treated with reduced intensity therapy.",
keywords = "alveolar rhabdomyosarcoma, D9602, D9803, embryonal rhabdomyosarcoma, fusion status, histology, low risk, outcomes, rhabdomyosarcoma",
author = "Arnold, {Michael A.} and Anderson, {James R.} and Gastier-Foster, {Julie M.} and Barr, {Frederic G.} and Skapek, {Stephen X.} and Hawkins, {Douglas S.} and Raney, {R. Beverly} and Parham, {David M.} and Teot, {Lisa A.} and Rudzinski, {Erin R.} and Walterhouse, {David O.}",
year = "2016",
month = "4",
day = "1",
doi = "10.1002/pbc.25862",
language = "English (US)",
volume = "63",
pages = "634--639",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features

T2 - A Report From the Children's Oncology Group

AU - Arnold, Michael A.

AU - Anderson, James R.

AU - Gastier-Foster, Julie M.

AU - Barr, Frederic G.

AU - Skapek, Stephen X.

AU - Hawkins, Douglas S.

AU - Raney, R. Beverly

AU - Parham, David M.

AU - Teot, Lisa A.

AU - Rudzinski, Erin R.

AU - Walterhouse, David O.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - BACKGROUND: Distinguishing alveolar rhabdomyosarcoma (ARMS) from embryonal rhabdomyosarcoma (ERMS) is of prognostic and therapeutic importance. Criteria for classifying these entities evolved significantly from 1995 to 2013. ARMS is associated with inferior outcome; therefore, patients with alveolar histology have generally been excluded from low-risk therapy. However, patients with ARMS and low-risk stage and group (Stage 1, Group I/II/orbit III; or Stage 2/3, Group I/II) were eligible for the Children's Oncology Group (COG) low-risk rhabdomyosarcoma (RMS) study D9602 from 1997 to 1999. The characteristics and outcomes of these patients have not been previously reported, and the histology of these cases has not been reviewed using current criteria.PROCEDURE: We re-reviewed cases that were classified as ARMS on D9602 using current histologic criteria, determined PAX3/PAX7-FOXO1 fusion status, and compared these data with outcome for this unique group of patients.RESULTS: Thirty-eight patients with ARMS were enrolled onto D9602. Only one-third of cases with slides available for re-review (11/33) remained classified as ARMS by current histologic criteria. Most cases were reclassified as ERMS (17/33, 51.5%). Cases that remained classified as ARMS were typically fusion-positive (8/11, 73%), therefore current classification results in a similar rate of fusion-positive ARMS for all clinical risk groups. In conjunction with data from COG intermediate-risk treatment protocol D9803, our data demonstrate excellent outcomes for fusion-negative ARMS with otherwise low-risk clinical features.CONCLUSIONS: Patients with fusion-positive RMS with low-risk clinical features should be classified and treated as intermediate risk, while patients with fusion-negative ARMS could be appropriately treated with reduced intensity therapy.

AB - BACKGROUND: Distinguishing alveolar rhabdomyosarcoma (ARMS) from embryonal rhabdomyosarcoma (ERMS) is of prognostic and therapeutic importance. Criteria for classifying these entities evolved significantly from 1995 to 2013. ARMS is associated with inferior outcome; therefore, patients with alveolar histology have generally been excluded from low-risk therapy. However, patients with ARMS and low-risk stage and group (Stage 1, Group I/II/orbit III; or Stage 2/3, Group I/II) were eligible for the Children's Oncology Group (COG) low-risk rhabdomyosarcoma (RMS) study D9602 from 1997 to 1999. The characteristics and outcomes of these patients have not been previously reported, and the histology of these cases has not been reviewed using current criteria.PROCEDURE: We re-reviewed cases that were classified as ARMS on D9602 using current histologic criteria, determined PAX3/PAX7-FOXO1 fusion status, and compared these data with outcome for this unique group of patients.RESULTS: Thirty-eight patients with ARMS were enrolled onto D9602. Only one-third of cases with slides available for re-review (11/33) remained classified as ARMS by current histologic criteria. Most cases were reclassified as ERMS (17/33, 51.5%). Cases that remained classified as ARMS were typically fusion-positive (8/11, 73%), therefore current classification results in a similar rate of fusion-positive ARMS for all clinical risk groups. In conjunction with data from COG intermediate-risk treatment protocol D9803, our data demonstrate excellent outcomes for fusion-negative ARMS with otherwise low-risk clinical features.CONCLUSIONS: Patients with fusion-positive RMS with low-risk clinical features should be classified and treated as intermediate risk, while patients with fusion-negative ARMS could be appropriately treated with reduced intensity therapy.

KW - alveolar rhabdomyosarcoma

KW - D9602

KW - D9803

KW - embryonal rhabdomyosarcoma

KW - fusion status

KW - histology

KW - low risk

KW - outcomes

KW - rhabdomyosarcoma

UR - http://www.scopus.com/inward/record.url?scp=85017061122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017061122&partnerID=8YFLogxK

U2 - 10.1002/pbc.25862

DO - 10.1002/pbc.25862

M3 - Article

C2 - 26756883

AN - SCOPUS:85017061122

VL - 63

SP - 634

EP - 639

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 4

ER -